JAAD Case Reports · 2018 · 19 citations · 3 references
MedicineDermatologyPharmacotherapyDermatopathologyHypersensitivityImmunopathologyDrug-induced Skin ReactionsInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersPruritic Skin DiseaseDrug-induced Skin EruptionsPembrolizumab TherapyPityriasis Rubra PilarisProgrammed Cell Death PathwaysProgrammed Death-1 BlockadeProgrammed Death-1 InhibitionPruritic DermatitisPsoriatic Disease
Numerous cutaneous adverse effects have been associated with programmed death 1 (PD-1) inhibitors including maculopapular eruptions, pruritus, eczema, lichenoid reactions, leukoderma, psoriasis, sarcoidosis, immunobullous disorders, and Stevens-Johnson syndrome.1,2 Here we report the first case, to our knowledge, of pityriasis rubra pilaris (PRP)-like erythroderma in the setting of anti–PD-1 therapy responsive to acitretin and topical steroids.
3
Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris
Laurence Feldmeyer, Alessio Mylonas, Olivier Demaria et al. · JAMA Dermatology · 2017 · 121 citations · Full text
Medicine, Dermatology, Immunology +17